Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Vascular Health and Risk Management|March 2, 2010
Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patientsJamison Wyatt, Shailesh Nandish, Rene Oliveros, et al.Current Atherosclerosis Reports|February 3, 2011
Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence?Shailesh Nandish, Oscar Bailon, Jamison Wyatt, et al.Current Atherosclerosis Reports|January 19, 2007
Statin therapy in cardiovascular diseases other than atherosclerosisDominique Beaudry, Kenneth E Stone, Suzanne Wetherold, et al.Endocrinology, Diabetes & Metabolism|March 1, 2019
Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetesMariam Alatrach, Christina Agyin, John Adams, et al.Clinical Cardiology|June 5, 2014
Hypoglycemia from a cardiologist's perspectiveVani P Sanon, Saurabh Sanon, Rushit Kanakia, et al.Current Cardiology Reports|June 20, 2020
The Role of Anticoagulation in COVID-19-Induced HypercoagulabilityJuan Simon Rico-Mesa, Daniel Rosas, Ashkan Ahmadian-Tehrani, et al.Diabetes Care|June 23, 2017
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?Muhammad Abdul-Ghani, Ralph A DeFronzo, Stefano Del Prato, et al.The American Journal of Cardiology|October 16, 2012
Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologistSaurabh Sanon, Rikesh Patel, Carrie Eshelbrenner, et al.Cardiovascular Diabetology|January 23, 2017
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetesThomas Jax, Alin Stirban, Arne Terjung, et al.Diabetes|March 21, 2024
Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT SubjectsXi Chen, Devjit Tripathy, Robert Chilton, et al.Pageof 6